Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

NewAmsterdam Pharma (NAMS) Return on Equity (2023 - 2025)

NewAmsterdam Pharma (NAMS) has disclosed Return on Equity for 3 consecutive years, with 0.29% as the latest value for Q4 2025.

  • Quarterly Return on Equity rose 14.0% to 0.29% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.29% through Dec 2025, up 14.0% year-over-year, with the annual reading at 0.28% for FY2025, 18.0% up from the prior year.
  • Return on Equity hit 0.29% in Q4 2025 for NewAmsterdam Pharma, up from 0.29% in the prior quarter.
  • In the past five years, Return on Equity ranged from a high of 0.21% in Q2 2025 to a low of 0.65% in Q1 2024.
  • Historically, Return on Equity has averaged 0.41% across 3 years, with a median of 0.39% in 2023.
  • Biggest five-year swings in Return on Equity: decreased -16bps in 2024 and later soared 41bps in 2025.
  • Year by year, Return on Equity stood at 0.57% in 2023, then rose by 25bps to 0.43% in 2024, then skyrocketed by 32bps to 0.29% in 2025.
  • Business Quant data shows Return on Equity for NAMS at 0.29% in Q4 2025, 0.29% in Q3 2025, and 0.21% in Q2 2025.